Category | Biotech

When de-risking, relationships matter: How using key strategies can get you to your next innovative partnership

Posted on 10 August 2015

An interview with Richard Brudnick, Senior VP, Corporate Development, Biogen De-risking has evolved from literature searches to the cultivation of many wide-ranging relationships throughout the life sciences strata, according to Richard Brudnick, Senior VP, Corporate Development at Biogen. In a recent interview, Brudnick outlined key strategies to accessing innovation and “de-risking” risk through collaboration.

Tags: , , , ,

Veracyte banks $40 million private placement

Posted on 28 April 2015

Veracyte has entered into a definitive agreement to sell approximately $40 million of its common stock in a private placement


MedImmune and Immunocore partner for melanoma combinations

Posted on 20 April 2015

Immunocore will conduct a Phase Ib/II clinical trial combining checkpoint inhibitors MEDI4736 (anti-PD-L1) and/or tremelimumab (anti-CTLA-4) with IMCgp100

Tags: , ,

Sanofi Pasteur and VBI Vaccines in formulation pact

Posted on 09 April 2015

VBI Vaccines has entered into a research collaboration with Sanofi Pasteur to apply VBI’s LPV (Lipid Particle Vaccine) formulation technology

Tags: , ,

Thrasos bags $21 million financing led by SR One

Posted on 01 April 2015

Thrasos Therapeutics has completed a $21M Series D financing led by BDC Capital and SR One

Morphosys regains MOR202 rights from Celgene

Posted on 27 March 2015

MorphoSys has regained rights to MOR202 from Celgene

Tags: , , , ,

Aeglea Biotherapeutics gains $44 million series B financing

Posted on 24 March 2015

Aeglea Biotherapeutics announced the closing of a $44 million Series B financing


Roche and Celldex in varlilumab and MPDL3280A combo pact

Posted on 18 March 2015

Celldex Therapeutics has entered into a clinical trial collaboration with Roche

Tags: , ,

Genzyme and Voyager in $845 million AAV gene therapy pact

Posted on 12 February 2015

Voyager Therapeutics and Genzyme announced a major strategic collaboration to discover, develop and commercialize novel gene therapies for severe CNS disorders

Tags: , , ,

Celgene and Zymeworks partner for bi-specific antibody therapeutics

Posted on 22 January 2015

Zymeworks announced a collaboration and licensing agreement with Celgene for the research, development, and commercialization of bi-specific antibody therapeutics enabled using Zymeworks’ proprietary Azymetric platform

Tags: , , ,